von Maur K
Ann Allergy. 1985 Sep;55(3):458-62.
Seven hundred eighty-two patients diagnosed as having either seasonal allergic rhinitis or perennial allergic rhinitis in a solo allergy practice were given five different antihistamine products representing each of the five classes of antihistamines. The following products were evaluated for 2 weeks each: tripelennamine, diphenhydramine, chlorpheniramine, hydroxyzine, and trimeprazine. Symptoms and side effects were graded 0 to 4. The more troublesome side effects, graded 3 or 4, were tabulated. The antihistamine products in order of increasing frequency of significant side effects were: trimeprazine, chlorpheniramine, hydroxyzine, diphenhydramine, and tripelennamine. The order of antihistamine preference by the patients was chlorpheniramine (27%), diphenhydramine (22%), tripelennamine (20%), hydroxyzine (16%), and trimeprazine (14%). Only seven of 758 patients (less than 1%) were unable to find an acceptable antihistamine class. Patients remained on their antihistamine class of first choice 78% of the time after 1 year, 71% after 3 years and 51% after 5 years. The antihistamine pack provides a rational approach to antihistamine selection in patients with allergic rhinitis.
在一家独立的过敏症诊所中,782名被诊断患有季节性过敏性鼻炎或常年性过敏性鼻炎的患者被给予了代表五类抗组胺药的五种不同抗组胺产品。对以下产品分别进行了为期2周的评估:曲吡那敏、苯海拉明、氯苯那敏、羟嗪和异丁嗪。症状和副作用按0至4级进行分级。对3级或4级更麻烦的副作用进行了列表统计。按显著副作用发生频率递增的顺序排列,抗组胺产品依次为:异丁嗪、氯苯那敏、羟嗪、苯海拉明和曲吡那敏。患者对抗组胺药的偏好顺序为氯苯那敏(27%)、苯海拉明(22%)、曲吡那敏(20%)、羟嗪(16%)和异丁嗪(14%)。758名患者中只有7人(不到1%)找不到可接受的抗组胺药类别。1年后,78%的患者继续使用他们首选的抗组胺药类别;3年后为71%;5年后为51%。抗组胺药组合为过敏性鼻炎患者选择抗组胺药提供了一种合理的方法。